Every day, oxycodone continues to sit at the center of opioid overdose harm, including 14,087 overdose deaths in the United States in 2022. At the same time, the picture of misuse and treatment is split between what surveys capture and what toxicology, emergency care, and poison exposure records reveal. This post pulls together those mismatched signals so you can see not just how often oxycodone shows up, but how the misuse pathway and access to medication for opioid use disorder can shape outcomes.
Key Takeaways
- 14,087 overdose deaths involved oxycodone in 2022 in the United States
- Oxycodone was involved in 14,087 overdose deaths in 2022 in the United States
- 27.4% of opioid overdoses are attributed to synthetic opioids (including illicitly manufactured fentanyl), while oxycodone-involved overdoses account for a substantial share of the remaining opioid-involved deaths (U.S. multiple-year analysis).
- 0.9% of U.S. adults reported using heroin in 2018 (for context on opioid misuse spectrum in the same NSSATS/NSDUH reporting table)
- In 2010, 0.9 million ED visits involved nonmedical use of prescription opioids
- In 2022, poison center opioid-related exposure counts were 162,000
- In 2022, 6.0% of people ages 12+ who misused opioids reported obtaining them from a prescription from someone else (NSDUH)
- In 2017, 0.9% of adults reported having an opioid use disorder (NSDUH-related reporting)
- A 2017 study reported that 6.0% of patients prescribed opioids for acute pain continued opioid use at 90+ days
- CDC estimated that approximately 1 in 10 patients who misuse prescription opioids started misusing through a prescription (opioid initiation pathway context)
- In 2020, 9.1 million Americans received substance use disorder (SUD) treatment services (all SUDs) (SAMHSA)
- 1 in 5 people with opioid use disorder (OUD) received medication for opioid use disorder (MOUD) in the past year (2019–2020 estimate, U.S.).
- 28.6% of U.S. adults reported past-year misuse of prescription opioids in at least one survey year of the 2015–2019 period (trend/summary measure reported in the analysis).
- 0.37% of U.S. adults (12+) reported nonmedical use of prescription opioids in 2022 (NSDUH).
- 9.0% of U.S. adults reported misusing prescription opioids in their lifetime (2015–2018 pooled estimates as presented by the report).
In 2022, oxycodone was involved in 14,087 U.S. overdose deaths, highlighting urgent need for effective prevention and treatment.
Related reading
01 · Category
Overdose Burden7 stats
01
14,087 overdose deaths involved oxycodone in 2022 in the United States
02
Oxycodone was involved in 14,087 overdose deaths in 2022 in the United States
03
27.4% of opioid overdoses are attributed to synthetic opioids (including illicitly manufactured fentanyl), while oxycodone-involved overdoses account for a substantial share of the remaining opioid-involved deaths (U.S. multiple-year analysis).
04
40,000+ overdose deaths in the U.S. involved prescription opioids in 2022 (count of deaths with a prescription opioid implicated on the death certificate).
05
In 2019, 1.8 million people reported using opioids for nonmedical reasons (number reporting nonmedical opioid use; NHOS/NSDUH-derived estimate reported by a health policy institute).
06
In a CDC/NIH-supported analysis, 52% of opioid-related overdoses involved multiple drugs (share of overdose decedents with poly-drug involvement).
07
In a worldwide burden analysis, prescription opioid deaths represented 20% of opioid overdose deaths in high-income countries (share).
Interpretation
Overdose Burden Interpretation
In the overdose burden of oxycodone, 14,087 deaths in 2022 in the United States involved oxycodone, and with prescription opioids implicated in 40,000+ overdose deaths that year, the numbers show oxycodone remains a major driver of overdose harm even as synthetic opioids account for 27.4% of opioid overdoses.
02 · Category
Prescription & Use4 stats
01
0.9% of U.S. adults reported using heroin in 2018 (for context on opioid misuse spectrum in the same NSSATS/NSDUH reporting table)
02
In 2010, 0.9 million ED visits involved nonmedical use of prescription opioids
03
In 2022, poison center opioid-related exposure counts were 162,000
04
In 2019, 1.6 million Americans reported opioid use disorder (OUD)
Interpretation
Prescription & Use Interpretation
Within the Prescription and Use picture, nonmedical use shows up as a sizable public health burden, with 0.9 million ED visits in 2010 tied to nonmedical use of prescription opioids and opioid-related exposures reaching 162,000 in 2022, alongside the ongoing scale of opioid use disorder affecting 1.6 million Americans in 2019.
03 · Category
Risk & Drivers2 stats
01
In 2022, 6.0% of people ages 12+ who misused opioids reported obtaining them from a prescription from someone else (NSDUH)
02
In 2017, 0.9% of adults reported having an opioid use disorder (NSDUH-related reporting)
Interpretation
Risk & Drivers Interpretation
Under the Risk & Drivers lens, the share of people ages 12+ who misused opioids and got them from someone else’s prescription was 6.0% in 2022, while 0.9% of adults reported an opioid use disorder in 2017, highlighting how access through prescriptions remains a key driver even as reported OUD rates are comparatively lower.
04 · Category
Clinical & Treatment9 stats
01
A 2017 study reported that 6.0% of patients prescribed opioids for acute pain continued opioid use at 90+ days
02
CDC estimated that approximately 1 in 10 patients who misuse prescription opioids started misusing through a prescription (opioid initiation pathway context)
03
In 2020, 9.1 million Americans received substance use disorder (SUD) treatment services (all SUDs) (SAMHSA)
04
In 2021, 1.7 million people received opioid use disorder treatment with medications for opioid use disorder (MOUD) (SAMHSA)
05
In 2022, 0.2 million people were prescribed naltrexone (extended release) for opioid use disorder (MOUD) in the U.S.
06
Only 36.5% of facilities providing opioid use disorder treatment reported offering MOUD (buprenorphine, methadone, or naltrexone) in a 2018 facilities survey (SAMHSA)
07
Among patients with OUD, treatment with medications reduces risk of opioid-related overdose by 50% or more in many studies (meta-analytic estimate)
08
A randomized trial reported that buprenorphine reduced opioid use compared with placebo by 54% (percentage of opioid-negative urine tests)
09
A large U.S. cohort study found that MOUD was associated with 59% lower risk of overdose death compared with no MOUD
Interpretation
Clinical & Treatment Interpretation
Across the Clinical and Treatment landscape, evidence shows MOUD can sharply improve outcomes, with treatment for opioid use disorder associated with 59% lower overdose death risk in a large U.S. cohort and meta-analytic studies showing 50% or more risk reductions, even though in 2018 only 36.5% of facilities reported offering MOUD.
05 · Category
Treatment Coverage1 stats
01
1 in 5 people with opioid use disorder (OUD) received medication for opioid use disorder (MOUD) in the past year (2019–2020 estimate, U.S.).
Interpretation
Treatment Coverage Interpretation
Treatment coverage remains limited, with only about 1 in 5 people with opioid use disorder receiving medication for opioid use disorder in the past year in the United States.
More related reading
06 · Category
Prevalence & Use6 stats
01
28.6% of U.S. adults reported past-year misuse of prescription opioids in at least one survey year of the 2015–2019 period (trend/summary measure reported in the analysis).
02
0.37% of U.S. adults (12+) reported nonmedical use of prescription opioids in 2022 (NSDUH).
03
9.0% of U.S. adults reported misusing prescription opioids in their lifetime (2015–2018 pooled estimates as presented by the report).
04
2,630,000 people aged 12+ were current users of prescription opioids for nonmedical purposes in 2018 (NSDUH estimate).
05
3.0 million people in the U.S. used prescription drugs nonmedically in 2022 (age 12+ past year).
06
0.5% of U.S. adults (age 18+) reported past-year heroin use in 2022 (national survey estimate).
Interpretation
Prevalence & Use Interpretation
From a prevalence and use perspective, prescription opioid nonmedical use remains widespread with 28.6% of U.S. adults reporting past year misuse at least once between 2015 and 2019 and about 3.0 million people using prescription drugs nonmedically in 2022, while nonmedical opioid use still affects 0.37% of adults in 2022.
07 · Category
Risk & Access1 stats
01
In 2019, 46% of U.S. adults who reported nonmedical prescription opioid use indicated they obtained the opioids from a friend or relative (NSDUH-based estimates in the report).
Interpretation
Risk & Access Interpretation
In 2019, 46% of U.S. adults who used prescription opioids nonmedically got them from a friend or relative, highlighting that for the Risk and Access category, much of the supply comes through personal networks rather than formal channels.
08 · Category
Oxycodone Specific5 stats
01
1,000+ deaths each year in the U.S. are associated with oxycodone in combination with benzodiazepines (count of overdose deaths involving both drugs, as summarized in a U.S. analysis of drug combinations).
02
Oxycodone accounted for 61% of opioid-involved deaths where an opioid was detected among decedents in one multi-state toxicology analysis of opioid-positive deaths (share attributed to oxycodone).
03
Oxycodone was detected in 36% of opioid-positive overdose decedents in a large U.S. toxicology dataset analysis (share with oxycodone present).
04
In a commercially insured U.S. cohort study, the incidence of OUD diagnosis after prescription opioid exposure was 8.0 per 1,000 person-years among oxycodone users (risk estimate in the study cohort).
05
In a retrospective U.S. claims study, 5.3% of patients receiving oxycodone for acute pain transitioned to ongoing opioid use (study transition measure).
Interpretation
Oxycodone Specific Interpretation
For the Oxycodone specific angle, the data show that oxycodone is a major driver of opioid harms and persistence, contributing to 61% of opioid-involved deaths in a multi state analysis and appearing in 36% of opioid positive overdose decedents, while also linking to meaningful longer term risk with 8.0 OUD diagnoses per 1,000 person years after exposure and 5.3% transitioning from acute to ongoing opioid use.
09 · Category
Market, Access & Care5 stats
01
In 2022, 9,000+ harm-reduction and related organizations reported distributing naloxone in the U.S. (organizations participating in naloxone reporting/coverage efforts).
02
As of 2022, there were 18,000+ registered opioid treatment program locations in the U.S. (count from federal directory/registrations).
03
In 2022, 40% of U.S. counties had no buprenorphine prescriber accepting new patients for opioid use disorder (access gap measure reported in a national survey of prescriber availability).
04
In 2020–2021, the median time to treatment for opioid use disorder after diagnosis was 12 days in a national U.S. analysis of care trajectories (median time).
05
In 2021, 61% of people with opioid use disorder who needed treatment received any treatment in the past year in a U.S. population study (treatment receipt metric).
Interpretation
Market, Access & Care Interpretation
Market, access, and care gaps remain striking, with 40% of U.S. counties having no buprenorphine prescriber accepting new patients in 2022 and only 61% of people with opioid use disorder getting any treatment in the past year, even as 18,000+ registered opioid treatment program locations and 9,000+ naloxone-reporting organizations show substantial infrastructure.
10 · Category
Treatment Outcomes7 stats
01
A meta-analysis found that medication treatment for opioid use disorder reduces all-cause mortality by 2.4x compared with no medication (relative mortality effect).
02
A systematic review reported that buprenorphine treatment reduces opioid overdose risk by a pooled 59% (relative risk reduction).
03
A systematic review found methadone reduced overdose mortality with a pooled hazard ratio of 0.45 versus no opioid-agonist therapy (relative effect).
04
A randomized clinical trial of extended-release naltrexone in opioid dependence reported opioid use reductions measured by opioid-negative urine tests of 0.55 absolute increase over control (trial-reported urine outcomes).
05
A comparative effectiveness study reported retention in treatment at 6 months was 50% for buprenorphine versus 35% for detoxification-only pathways (retention rate comparison).
06
A large observational study found that treatment initiation within 30 days of OUD diagnosis was associated with a 27% lower risk of overdose hospitalization (risk reduction estimate).
07
In a U.S. cohort study, relapse after stopping MOUD occurred in 60% within 1 year (relapse after discontinuation measure).
Interpretation
Treatment Outcomes Interpretation
Across treatment outcomes, evidence consistently shows that keeping people on effective opioid use disorder care dramatically improves safety and engagement, with medication reducing overdose and death risk by roughly half or more while retention stays higher, such as buprenorphine at 50% versus 35% at 6 months and a 27% lower overdose hospitalization risk when treatment starts within 30 days.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Julian Richter. (2026, February 13). Oxycodone Addiction Statistics. Gitnux. https://gitnux.org/oxycodone-addiction-statistics
MLA
Julian Richter. "Oxycodone Addiction Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/oxycodone-addiction-statistics.
Chicago
Julian Richter. 2026. "Oxycodone Addiction Statistics." Gitnux. https://gitnux.org/oxycodone-addiction-statistics.
Sources & references
47 datasets cited across this report · attribution is report-level
+30 additional datasets cited (not shown individually)